Author:
Zhao Lu,Wang Na,Zhang Dou,Jia Yingjie,Kong Fanming
Abstract
RET gene plays significant roles in the nervous system and many other tissues. Rearranged during transfection (RET) mutation is related to cell proliferation, invasion, and migration. Many invasive tumors (e.g., non-small cell lung cancer, thyroid cancer, and breast cancer) were found to have changes in RET. Recently, great efforts have been made against RET. Selpercatinib and pralsetinib, with encouraging efficacy, intracranial activity, and tolerability, were approved by the Food and Drug Administration (FDA) in 2020. The development of acquired resistance is inevitable, and a deeper exploration should be conducted. This article systematically reviewed RET gene and its biology as well as the oncogenic role in multiple cancers. Moreover, we also summarized recent advances in the treatment of RET and the mechanism of drug resistance.
Funder
National Natural Science Foundation of China
Reference85 articles.
1. RET signaling pathway and RET inhibitors in human cancer;Regua;Front Oncol,2022
2. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2;Olmedo;World J Clin Oncol,2022
3. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC;Li;J Thorac Oncol,2021
4. State-of-the-Art strategies for targeting RET-dependent cancers;Subbiah;J Clin Oncol,2020
5. Roles of the RET proto-oncogene in cancer and development;Takahashi;Jma J,2020
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献